A London coroner concluded that 19-year-old law student Josephine Nasr died of cardiac arrhythmia caused by congenital myocardial bridging combined with an electrolyte imbalance from hypoglycemia linked to prescribed tirzepatide. The inquest heard that drug-induced vomiting could trigger the fatal…
A coroner in London has concluded that a 19-year-old California law student died of cardiac arrhythmia caused by congenital myocardial bridging combined with an electrolyte imbalance that resulted from hypoglycemia linked to prescribed tirzepatide . Josephine Nasr, a second-year law student studying abroad at the University of East London, was found dead in her dormitory room in London on September 23, 2025.
At an inquest heard last week at East London Coroner's Court, Coroner Graeme Irvine determined that Nasr had been prescribed tirzepatide by a doctor in California and that the drug's effects contributed to her death. Pathologist Alan Bates performed the autopsy and found myocardial bridging, a congenital condition in which a band of heart muscle lies over a segment of a coronary artery. Bates described Nasr as "an otherwise healthy young woman." The bridging had produced no known symptoms during her life; it was discovered after death.
The case is unusual in tirzepatide's adverse-event record because of the patient profile. Nasr was 19, her body mass index placed her in the overweight category rather than the obese category, and she had no known cardiac diagnosis. The fatal pathway identified by the coroner, running from vomiting through hypoglycemia and electrolyte imbalance to arrhythmia, is distinct from the drug's most commonly reported gastrointestinal side effects. An empty vial of tirzepatide found in her room connected the death to the medicine.
The coroner's conclusion does not hold that the drug alone killed Nasr. It holds that tirzepatide contributed a metabolic disturbance that acted on an anatomical vulnerability that had been silent for 19 years. That distinction matters for how the case should be read by clinicians and researchers: as a signal about a rare interaction between an increasingly common drug and an undiagnosed congenital cardiac anomaly, not as evidence that the drug is inherently unsafe. It is also a reminder that the findings rest on the coroner's and pathologist's assessment of the history and the autopsy. No antemortem or postmortem measurements of glucose, electrolytes, or drug concentrations have been disclosed.
Nasr had visited her family home in a gated community in Corona roughly one week before she died. On the evening of September 23, 2025, at around 8:30 p.m., she told her father George Nasr, her mother Lorin Mansour, and her sister Anastasia Nasr that she felt nauseous and had been vomiting.
Anastasia Nasr, concerned that her sister was becoming dehydrated from the vomiting, arranged for a private healthcare provider to give IV fluids. When Nasr stopped responding, her sister asked the university to perform a welfare check. Security staff and a nurse found Nasr lying on the bathroom floor, and a paramedic with the London Ambulance Service pronounced her dead at the scene. University staff found an empty vial of tirzepatide in her room.
The empty vial ties the drug to the scene, but it does not establish the timing of the last dose. Tirzepatide is injected once weekly, so the vial could have held a dose taken days before, or a dose taken closer to death; the record does not say which. The location where she was found is consistent with collapse during an episode of gastrointestinal illness, and the fact that she had been vomiting for some time beforehand is the clinical detail on which the coroner's pathway rests.
Her father told the inquest: "She always helped others before herself." He also said: "She loved traveling and the ocean." Her mother, Lorin Mansour, said: "We are part of the Coptic Church, and the way Josephine was willing to help people showed that she lived her faith." The family's statements do not bear on the medical conclusions, but they establish what the inquest also noted: a young woman with no known illness before the gastrointestinal episode that preceded her death.
The inquest heard that tirzepatide-induced vomiting could cause hypoglycemia, and that hypoglycemia could in turn cause an electrolyte imbalance capable of producing a dangerous arrhythmia. The stress of the electrolyte imbalance, Irvine concluded, could have worsened Nasr's myocardial bridging, which can itself trigger arrhythmia. His conclusion combined the two findings: the fatal arrhythmia arose from the intersection of an anatomical vulnerability and an acute metabolic disturbance. Whether the private healthcare provider actually administered IV fluids before Nasr stopped responding was not stated in the public account of the hearing.
Myocardial bridging is a congenital variant, not an acquired disease. Coronary arteries normally run along the surface of the heart. In myocardial bridging, a band of muscle passes over a segment of a coronary artery, most often the left anterior descending artery, and compresses it during each contraction. The compression is not confined to systole; release of the squeeze is delayed into early diastole, which is precisely when most coronary flow reaches the muscle. When the heart rate rises, diastole shortens, the delay consumes a larger fraction of the filling time, and the oxygen supply falls at the moment the heart's demand for it rises. Most people with a bridge never know they have it. Under metabolic stress, however, the bridge can produce ischemia, arrhythmia, and in rare cases sudden death.
The metabolic limb of the coroner's pathway begins with repeated vomiting. Each episode removes water, sodium, potassium, chloride, and hydrogen ions. Loss of hydrogen ion and chloride produces a metabolic alkalosis, and the volume contraction triggers aldosterone release, which drives renal potassium excretion. The alkalosis itself shifts potassium into cells and lowers ionized calcium. The net effect is depletion of the two cations most important to cardiac repolarization.
Potassium is the electrolyte that matters most in this sequence. Hypokalemia slows the delayed rectifier potassium channels that terminate the ventricular action potential, lengthening the interval from the onset of depolarization to the completion of repolarization. A prolonged action potential creates the conditions for early afterdepolarizations, the cellular trigger for torsades de pointes and other polymorphic ventricular arrhythmias. The Mayo Clinic lists nausea and vomiting among the possible side effects of tirzepatide, and for most patients those effects are transient and tolerable. For a patient who cannot keep fluids down for an extended period, the same physiology becomes a volume and electrolyte emergency.
Hypoglycemia adds a second, independent stress. The fall in blood glucose triggers a counter-regulatory surge of epinephrine, glucagon, cortisol, and growth hormone. Epinephrine raises heart rate and contractility, increases myocardial oxygen demand, shifts potassium into cells, and is itself associated with QT prolongation. For a patient with myocardial bridging, tachycardia is exactly the wrong cardiovascular state: the faster the heart beats, the more forcefully the bridged segment compresses the artery and the less time remains for diastolic flow. The same catecholamine surge that demands more oxygen therefore worsens the mechanical obstruction that limits supply. Hypoglycemia also carries a documented association with ventricular arrhythmia in people with diabetes, mediated through these same mechanisms.
The coroner's conclusion is that the bridging and the metabolic derangement were jointly responsible for the fatal arrhythmia. That is a reasoned inference from the autopsy and the clinical history, and it is consistent with what is known about both conditions. One creates a fixed structural vulnerability; the other produces the electrical and hemodynamic disturbance that exposes it. What the inquest record does not provide is confirmation at the level of measurement. No glucose or electrolyte values were reported, and no postmortem biochemistry was presented to verify that the imbalance the coroner described actually existed. Under the balance-of-probabilities standard applied to inquests, a coherent chain of plausible links can support a conclusion; a clinical researcher would want the measurements before calling the pathway established.
Tirzepatide is a dual GIP and GLP-1 receptor agonist sold under two brand names: Mounjaro , for type 2 diabetes, and Zepbound , for weight management and obstructive sleep apnea. The peptide potentiates insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastric emptying, and strengthens satiety signals. Its action on both incretin receptors, rather than on the GLP-1 receptor alone, distinguishes it from earlier drugs in its class.
The glucose dependence of the insulinotropic effect is the reason tirzepatide carries a low intrinsic risk of hypoglycemia in clinical trials when used without sulfonylureas or insulin. At low plasma glucose concentrations, the incretin signal does not amplify insulin secretion. That makes the coroner's pathway instructive rather than paradoxical. The hypoglycemia in Nasr's case was most plausibly a complication of gastrointestinal intolerance and inadequate intake, not a direct effect of the drug's insulinotropic mechanism. Repeated vomiting removed glucose and fluids; the drug's appetite suppression and delayed gastric emptying reduced intake; and a stressed, fasting body has limited glycogen reserves. On that background, glucose falls, and the counter-regulatory response to the fall does the cardiac damage.
Delayed gastric emptying deserves emphasis. A patient who is vomiting on the days after an incretin injection cannot rely on oral fluids to correct dehydration, because the stomach is not passing its contents at the normal rate. The drug also persists in the body well beyond the day of the injection; its metabolic effects do not switch off when a patient stops eating or stops taking the medication. Vomiting after a dose is therefore a different clinical problem from vomiting in a patient on no medication: it combines ongoing loss with slowed replacement and a drug effect that will continue for days.
The indexed case literature contains a parallel. A case report published in the American Journal of Case Reports in 2026 describes starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman. The biochemistry differs from Nasr's: euglycemic ketoacidosis features normal glucose, low insulin, high glucagon, and ketosis, while the coroner's pathway in Nasr's case centers on low glucose. The two cases share a root cause: profound and prolonged caloric deprivation on a drug background that suppresses appetite and slows gastric emptying. Both occurred in patients outside the classic type 2 diabetes or obesity population. For peptide researchers, the lesson is that the metabolic risks of incretin therapy in non-diabetic users are primarily risks of insufficient intake and gastrointestinal loss, and that intercurrent illness can convert a manageable side effect into a metabolic emergency.
Peptide Atlas's registry contains 251 registered clinical trials for tirzepatide. The phase breakdown lists 5 Phase 2 trials, 2 Phase 4 trials, and 1 Phase 3 trial, with 10 trials currently marked as recruiting. The registry indexes 188 PubMed papers on the drug and maintains a reference page at https://peptideatlas.co/peptides/tirzepatide that aggregates the trial, literature, and testing data. The structured phase and status fields cover a subset of the 251 trials, so the counts should be read as the slice of the portfolio tagged in the registry, not as the full global development program. That slice still shows the…
Peptides referenced: Tirzepatide, Growth Hormone, Glucagon, GLP-1.
Related reading: Lilly Lifts 2026 Guidance as Tirzepatide Sales Surge, Peptide Rivals Split, Meta-Analyses Question Long-Term Value of GLP-1 Weight-Loss Drugs, Gedeon Richter and Adalvo Expand Partnership to Tirzepatide Therapies, Tirzepatide tied to 32% lower MACE risk in real-world diabetes cohort.